CM
ORKA

Caption Management’s Oruka Therapeutics ORKA Stock Holding History

Caption Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,300
Closed -$217K – 2165
2025
Q3 		$217K Buy
+11,300
New +$167K ﹤0.01% 1457

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Caption Management's ORKA Position: Q4 2025 in Review

Caption Management sold out of Oruka Therapeutics (ORKA) in Q4 2025, closing a stake of 2,000 shares — an estimated $38.5K sold.

Caption Management first reported a position in ORKA in Q3 2025 and held it in 1 quarter. The position peaked at $38.5K in Q3 2025. 143 funds tracked by Wall St. Rank hold ORKA as of Q4 2025.

  • Caption Management reported no remaining Oruka Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Caption Management sold 2,000 Oruka Therapeutics shares in Q4 2025, an estimated $38.5K.
  • Caption Management first reported a position in Oruka Therapeutics in Q3 2025 and held it in 1 quarter.
  • Caption Management's Oruka Therapeutics position peaked at $38.5K in Q3 2025.
  • 143 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.